The prevalence of type 2 diabetes, along with related conditions, such as metabolic syndrome and obesity, has increased ...

Shares of Regeneron Pharmaceuticals Inc. REGN slumped 0.17% to $1,012.82 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.90% ...

This week, the FDA granted approval to Sanofi SNY and Regeneron’s REGN blockbuster drug, Dupixent, for its sixth indication.

Biotech company Regeneron Pharmaceuticals lost a bid on Friday to be held immune from allegations that it misused a patented ...

Regeneron Pharmaceuticals Inc (REGN) stock saw a decline, ending the day at $1014.59 which represents a decrease of $-25.68 or -2.47% from the prior close of $1040.27. The stock opened at $1037.5 and ...